Post-Grant Review Of Multiple Sclerosis Treatment Patent Sought

(July 14, 2016, 11:49 AM EDT) -- ALEXANDRIA, Va. — A claimed method of treating multiple sclerosis (MS) with the injection of 40 milligrams of glatiramer acetate (GA) thrice weekly should not have received federal patent protection, Amneal Pharmaceuticals LLC alleges in a July 12 petition for post-grant review before the Patent Trial and Appeal Board (Amneal Pharmaceuticals LLC v. Yeda Research & Development Co. Ltd., No. PGR2016-00028, PTAB).

(Petition available. Document #16-160718-019C.)

According to Amneal, “the Board need only resolve one question” — whether the specification of Yeda Research & Development Co....
To view the full article, register now.